O
AVTX icon

OrbiMed’s Avalo Therapeutics AVTX Stock Holding History

OrbiMed’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.09M Sell
475,165
-712,135
-60% -$11.1M 0.15% 85
2025
Q4 		$21.6M Sell
1,187,300
-162,000
-12% -$2.73M 0.44% 57
2025
Q3 		$17.1M Buy
1,349,300
+382,300
+40% +$3.29M 0.41% 57
2025
Q2 		$4.83M Hold
967,000
– – 0.12% 78
2025
Q1 		$7.75M Hold
967,000
– – 0.19% 69
2024
Q4 		$7.18M Hold
967,000
– – 0.15% 76
2024
Q3 		$9.19M Buy
+967,000
New +$9.97M 0.17% 80

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.41B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.71B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $1.6B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $15.3B AUM 50.95% 1-Year Est. Return